Clinical Trial Detail

NCT ID NCT02115282
Title Exemestane With or Without Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors National Cancer Institute (NCI)

breast carcinoma


Exemestane + Goserelin

Entinostat + Exemestane + Goserelin

Age Groups: adult senior

Additional content available in CKB BOOST